FMC - River Hills is a medicare approved dialysis facility center in Huntington, West Virginia and it has 24 dialysis stations. It is located in Cabell county at 5170 Us Rte 60 East, Huntington, WV, 25705. You can reach out to the office of FMC - River Hills at (304) 733-0004. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC - River Hills has the following ownership type - Profit. It was first certified by medicare in May, 2010. The medicare id for this facility is 512535 and it accepts patients under medicare ESRD program.
| Name | FMC - River Hills |
|---|---|
| Location | 5170 Us Rte 60 East, Huntington, West Virginia |
| No. of Dialysis Stations | 24 |
| Medicare ID | 512535 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 5170 Us Rte 60 East, Huntington, West Virginia, 25705 | |
| (304) 733-0004 | |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
| NPI Number | 1437489432 |
| Organization Name | Fresenius Medical Care River Hills |
| Doing Business As | Fresenius Medical Care Himg Dialysis Center, Llc |
| Address | 5170 Us Route 60 E Huntington, West Virginia, 25705 |
| Phone Number | (304) 733-0004 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 63% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 20% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 17% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 54% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 35% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 14% |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 57% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 22% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 21% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 53% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 35% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 12% | 12% |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 82% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 18% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 56% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 34% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 12% |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 53 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 2 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 111 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 940 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
| Adult patients getting regular peritoneal dialysis at the center | 12 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 85 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 94 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC - River Hills with elevated calcium levels.
| Patients with hypercalcemia | 138 |
| Hypercalcemia patient months | 1216 |
| Patients with Serumphosphor | 152 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 25 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 90 |
| Patient months included in arterial venous fistula and catheter summaries | 774 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 62 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 26 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 117 |
| Hospitalization Rate in facility | 212.1 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 326 |
| Hospitalization Rate: Lower Confidence Limit | 147.3 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC - River Hills were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 27 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 36.3 |
| Readmission Rate: Lower Confidence Limit | 18.8 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC - River Hills get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .18 (Better than Expected) |
| SIR: Upper Confidence Limit | .61 |
| SIR: Lower Confidence Limit | .03 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC - River Hills's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 92 |
| Transfusion Rate in facility | 48.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 96.9 |
| Transfusion Rate: Lower Confidence Limit | 26.4 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC - River Hills lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 538 |
| Mortality Rate in facility | 19.8 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 24.1 |
| Mortality Rate: Lower Confidence Limit | 16.1 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago
J Robert Pritchard Dialysis Center Location: 1690 Medical Center Dr, Huntington, West Virginia, 25701 Phone: (304) 399-1290 |
FMC - River Hills Location: 5170 Us Rte 60 East, Huntington, West Virginia, 25705 Phone: (304) 733-0004 |
FMS Cabell Huntington Dialysis Centers, Llc Location: 1500 17th Street, Huntington, West Virginia, 25701 Phone: (304) 525-8091 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.
› Verified 4 days ago